Core Insights - Artiva Biotherapeutics is advancing its AlloNK program for refractory rheumatoid arthritis (RA), with initial clinical response data expected in the first half of 2026 [1][10] - The company has received FDA Fast Track designation for AlloNK in refractory RA, highlighting the significant unmet need in this patient population [3] - Artiva's financial position remains robust, with cash, cash equivalents, and investments totaling $108.0 million as of December 31, 2025, expected to fund operations into Q2 2027 [1][10] Company Developments - Artiva has prioritized refractory RA as the lead indication for AlloNK, aiming to redefine treatment paradigms by combining deep B-cell depletion with an outpatient-ready profile [2][3] - The company has successfully enrolled patients across various autoimmune indications, with a focus on refractory RA, and plans to provide initial clinical response data from at least 15 patients [3][10] - Recent leadership appointments include Subhashis Banerjee, M.D. as chief medical officer and Thad Huston as chief financial officer, enhancing the company's expertise in rheumatology and financial strategy [4] Clinical and Financial Highlights - AlloNK plus rituximab has demonstrated deep and consistent B-cell depletion, achieving non-quantifiable peripheral CD19+ B-cell levels by Day 13 in treated patients [3] - The regimen has shown a favorable safety profile, with no reported cases of cytokine release syndrome or other severe adverse effects, facilitating strong patient enrollment [3] - For the year ended December 31, 2025, Artiva reported a net loss of $83.9 million, an increase from a net loss of $65.4 million in 2024, with research and development expenses rising to $69.5 million [10][15]
Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights